GlassScriptPhysician profile
Amer Akhrass
NPI 1326005786
$26,837.77
in general payments reported to CMS, 2019-2025
61 companies · $4,426 in 2025
The $4,426 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,200 · 2020: $3,733 · 2021: $3,492 · 2022: $4,630 · 2023: $3,444 · 2024: $3,913 · 2025: $4,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,567.58 |
| Education | $215.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,367.37 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $3,058.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $2,470.54 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,849.69 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,708.12 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,193.15 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,067.13 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $999.77 | 2019-2025 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $879.68 | 2019-2025 | Verquvo, Belsomra, Lagevrio |
| Collegium Pharmaceutical, INC. | $834.68 | 2019-2024 | Xtampza, Belbuca |
| Astellas Pharma US INC | $795.91 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $762.59 | 2019-2023 | Spiriva Respimat, Stiolto Respimat, Tradjenta |
| Sanofi-Aventis U.S. LLC | $739.60 | 2019-2023 | |
| Amgen INC. | $638.92 | 2019-2025 | Repatha, Otezla, Otezla |
| Daiichi Sankyo INC. | $569.01 | 2019-2024 | Injectafer |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Akhrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.